Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich, Switzerland

* Reuters is not responsible for the content in this press release.

Mon Mar 30, 2009 8:30am EDT 

Webcast Alert: Oxygen Biotherapeutics, Inc. Investor Meeting in Zurich,
Switzerland

COSTA MESA, Calif., March 30 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics,
Inc. (OTC Bulletin Board: OXBO) will hold an investor presentation meeting for
shareholders, prospective investors and interested parties in Zurich,
Switzerland on April 1, 2009. The purpose of the meeting will be to update the
investment community on the company's business.

Company chairman and CEO Chris J. Stern will be available to answer
shareholder questions along with the co-chairs of the company's medical
advisory board, Dr. Bruce D. Spiess, M.D., FAHA - Professor Anesthesiology and
Emergency Medicine, VCURES/ VCU Med Center Richmond, Virginia and Dr. Ross
Bullock, M.D. Ph.D.- Professor of Neurosurgery, University of Miami, Miami,
Florida. 

The three will be in Switzerland in connection with the clinical investigator
meeting, a formal initiating step for the Swiss Phase II clinical trial of
Oxycyte(R) in traumatic brain injury. Oxycyte is the Company's perfluorocarbon
(PFC) therapeutic oxygen carrier.

The meeting will be webcast live with the webcast available via the investor
relations page of the company website.
    Meeting details are as follows:
          Location:   Radisson SAS Zurich Airport Hotel
          Time:       1:00 p.m. - 3:00 p.m. local time (7:00 a.m. - 9:00
                      a.m. eastern time)
          Language:   The meeting language will be English


"This will give European investors a chance to participate in a discussion
with management and key researchers," said Stern. "We are also planning a
meeting of this type in the U.S. later this year." 

    What:     Live webcast of Zurich Investor Meeting

    When:     April 1, 2009 at 1:00 p.m. Zurich time (7:00 a.m. EDT)

    Where:    The live webcast will be available via the investor relations
              page of the company website at www.Oxybiomed.com or directly
              at: http://www.videonewswire.com/event.asp?id=57069

    How:      Live over the Internet -- Simply log on to the web at the
              address above.

    Contact:  Abe Wischnia of Abe Wischnia & Associates at 619-795-2345


About Oxygen Biotherapeutics, Inc. 

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative
pharmaceuticals and medical devices in the field of oxygen therapeutics and
continuous substrate monitoring. The company has under development a
perfluorocarbon therapeutic oxygen carrier and liquid ventilation product
(Oxycyte(R)) and an implantable glucose sensor. These products are based upon
core technologies that include biomedical applications for PFCs and medical
and industrial applications for biosensors. Each of the product candidates is
designed with advantages over currently marketed products in major markets
including traumatic brain injury, sickle cell crisis pain, trauma, wound care,
acute respiratory distress syndrome, stroke, myocardial infarction, surgery,
and diabetes. More information is available at www.oxybiomed.com.


Minimum Requirements to listen to broadcast:
 
The Windows Media Player software, downloadable free from 
http://www.microsoft.com and at least a 56Kbps connection to the Internet.

If you experience problems listening to the webcast, send an E-mail to:
webcast@multivu.com.



SOURCE  Oxygen Biotherapeutics, Inc.

Abe Wischnia of Abe Wischnia & Associates, +1-619-795-2345
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.